The decoding of the proteome is revolutionizing the way diseases are diagnosed, treated, and prevented.
Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making.
Our Solutions
We offer a versatile portfolio of proprietary proteomics services, software, and kits. We make these widely available for pharmaceutical and biotechnology researchers and proteomics experts.
Our solutions provide a multi-dimensional view of protein expression, function, and structure in all major sample types – cells, tissues, or body fluids – across human and non-human species.
Our Technology
Biognosys is the leading inventor and developer of mass spectrometry-based proteomics solutions. With market leading proteome coverage and sample throughput we enable simultaneous quantification of thousands of proteins across thousands of samples.
Our Facility
From our global headquarters just outside of Zurich, we operate one of the largest high-end mass spectrometry laboratories worldwide for Large-Scale Discovery Proteomics contract research.
Our Data Competence
Biognosys has analyzed a vast amount of proteomics data and developed an industry-leading understanding of the proteome. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research.
Global Presence
Founded in 2008 as a spin-off from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys today is an established leader in next-generation proteomics. With employees based across Switzerland, Europe, and US, and an extensive network of collaborators and distributors, Biognosys supports a global customer base of life science researchers across industry and academia.
Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making.
Our Solutions
We offer a versatile portfolio of proprietary proteomics services, software, and kits. We make these widely available for pharmaceutical and biotechnology researchers and proteomics experts.
Our solutions provide a multi-dimensional view of protein expression, function, and structure in all major sample types – cells, tissues, or body fluids – across human and non-human species.
Our Technology
Biognosys is the leading inventor and developer of mass spectrometry-based proteomics solutions. With market leading proteome coverage and sample throughput we enable simultaneous quantification of thousands of proteins across thousands of samples.
Our Facility
From our global headquarters just outside of Zurich, we operate one of the largest high-end mass spectrometry laboratories worldwide for Large-Scale Discovery Proteomics contract research.
Our Data Competence
Biognosys has analyzed a vast amount of proteomics data and developed an industry-leading understanding of the proteome. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research.
Global Presence
Founded in 2008 as a spin-off from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys today is an established leader in next-generation proteomics. With employees based across Switzerland, Europe, and US, and an extensive network of collaborators and distributors, Biognosys supports a global customer base of life science researchers across industry and academia.
Location: Switzerland, Zurich, Schlieren
Employees: 51-200
Total raised: $5M
Founded date: 2008
Investors 2
| Date | Name | Website |
| - | North Shor... | nsiv.org |
| - | Syngenta V... | syngentagr... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.07.2017 | Series C | $5M | - |
Mentions in press and media 21
| Date | Title | Description |
| 08.12.2024 | Bridging the Gap: The Intersection of Measurement Technology and Software Development | In the world of science and technology, precision is paramount. The quest for accuracy drives innovation, especially in measurement devices. A recent case highlights the complexities faced by engineers in this field, revealing a landscape w... |
| 06.12.2024 | IonOpticks' Custom Chromatography Column to Become Biognosys' Standard for High-Quality Proteomic Insights | MELBOURNE, Australia and ZURICH, Dec. 6, 2024 /PRNewswire/ -- Today, IonOpticks, a world leading provider of chromatography solutions, and Biognosys, a global leader in mass spectrometry-based proteomics contract research services, announce... |
| 23.05.2024 | Venture Leaders Biotech 2024: Captains Blog by Maria Van Dongen, CEO of Allegria Therapeutics, and Gabriel Liguori, CEO of TissueLabs | Venture Leaders Biotech 2024: Captains Blog by Maria Van Dongen, CEO of Allegria Therapeutics, and Gabriel Liguori, CEO of TissueLabs 23.05.2024 12:30, Rita Longobardi linkedIn facebook twitter instagram youtube --> In mid-May, the ten V... |
| 05.01.2023 | Biognosys en Bruker vormen een partnerschap voor Advanced Proteomics CRO Services voor wereldwijde biofarmaceutische en biomarkerklanten | Het nieuwe strategische partnerschap heeft tot doel de toegang tot de toonaangevende CRO-diensten van Biognosys en Spectronaut®-softwaretools voor onbevooroordeelde proteomics en epiproteomics te verbreden. Verwacht wordt dat het proteomics... |
| 05.01.2023 | Biognosys y Bruker se asocian para ofrecer servicios avanzados de proteómica CRO a clientes globales de biofarmacia y biomarcadores | La nueva asociación estratégica tiene como objetivo ampliar el acceso a los servicios de CRO líderes de Biognosys y a las herramientas de software Spectronaut® para la proteómica y epiproteómica imparciales. Se espera que beneficie a la inv... |
| 05.01.2023 | Biognosys et Bruker forment un partenariat pour offrir des services avancés de recherche sous contrat (CRO) en protéomique aux clients mondiaux des secteurs de la biopharmaceutique et des biomarqueurs... | Ce nouveau partenariat stratégique vise à élargir l'accès aux principaux services CRO de Biognosys et aux outils logiciels Spectronaut® pour la protéomique et l'épiprotéomique non biaisées. Ce partenariat devrait profiter à la recherche dan... |
| 05.01.2023 | Biognosys und Bruker schließen Partnerschaft für CRO-Dienstleistungen im Bereich der fortschrittlichen Proteomik für globale Biopharma- und Biomarker-Kunden | Neue strategische Partnerschaft zielt darauf ab, den Zugang zu führenden CRO-Dienstleistungen und Spectronaut®-Softwaretools von Biognosys für unverzerrte Proteomik und Epiproteomik zu erweitern Es wird erwartet, dass die Proteomforschung, ... |
| 05.01.2023 | Biognosys e Bruker formano una partnership per i servizi CRO di proteomica avanzata per i clienti globali di biofarmaci e biomarcatori | Una nuova partnership strategica mira ad ampliare l'accesso ai principali servizi CRO di Biognosys e agli strumenti software Spectronaut® per la proteomica e l'epiproteomica imparziali Si prevede che andrà a beneficio della ricerca sulla pr... |
| 04.01.2023 | Brucker acquires a majority stake in Biognosys | |
| 04.10.2022 | A new base for three Swiss startups |
Show more